|
WO2020254289A1
|
|
N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
|
|
AR115564A1
|
|
PYRIDINIL AND PYRAZINIL- (AZA) INDOLSULFONAMIDES
|
|
TW202016088A
|
|
Pyridinyl and pyrazinyl-(aza)indolsulfonamides
|
|
EP3584244A1
|
|
Substituted alkoxypyridinyl indolsulfonamides
|
|
TW201831448A
|
|
(AZA)Indole- and benzofuran-3-sulfonamides
|
|
US2017151215A1
|
|
Use of rotigotine for treating the restless leg syndrome
|
|
WO2015079010A2
|
|
Pharmaceutical composition comprising lacosamide and levetiracetam
|
|
EP2878296A1
|
|
Pharmaceutical composition comprising lacosamide and levetiracetam
|
|
TW201431570A
|
|
Multi-day patch for the transdermal administration of rotigotine
|
|
GB201223244D0
|
|
Micrornas as therapeutics and biomarkers for epilepsy
|
|
CN103946237A
|
|
Albumin binding antibodies and binding fragments thereof
|
|
CN103561727A
|
|
Once daily formulation of lacosamide
|
|
EP2621893A1
|
|
Process for the preparation of amino acid derivatives
|
|
EP2559435A1
|
|
Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
|
|
KR20170023772A
|
|
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
|
|
EP2468261A1
|
|
Formulation of lacosamide
|
|
EP2487152A1
|
|
Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
|
|
EP2378291A1
|
|
Lacosamide detection assay
|
|
US2010256179A1
|
|
Combination therapy for pain in painful diabetic neuropathy
|
|
CA2739741A1
|
|
Novel process for the preparation of amino acid derivatives
|
